摘要
目的 分析胰头十二指肠切除术后替吉奥辅助化疗对老年胰腺癌患者预后及免疫功能的影响。方法 选取2011年1月至2014年1月本院收治的80例老年胰腺癌患者为研究对象,以抽签法将入选患者分为对照组与研究组,每组各40例。两组患者均行胰头十二指肠切除术,术后对照组患者联合吉西他滨行辅助化疗,研究组患者联合替吉奥行辅助化疗。比较两组患者治疗前后血清肿瘤标志物、免疫球蛋白（Ig）水平、近期疗效、不良反应发生率及生存率。结果 治疗后两组患者血清CA19-9、CA50、CA125及CA242水平均较治疗前降低（P〈0.05）,研究组患者血清各肿瘤标志物水平均显著低于对照组（P〈0.05）。治疗后两组患者血清Ig G、Ig A、Ig M水平均较治疗前升高（P〈0.05）,研究组患者各Ig水平均显著高于对照组（P〈0.05）。研究组患者近期总有效率明显高于对照组（χ^2=4.013,P〈0.05）。两组患者厌食、乏力、恶心、皮疹、腹泻的发生率及总不良反应发生率比较差异均无显著性（P〉0.05）。研究组患者治疗后6个月、1年、2年的生存率均优于对照组（P〈0.05）。结论 胰头十二指肠切除术后替吉奥辅助化疗对老年胰腺癌的效果确切,明显提高患者的免疫功能,改善预后。
Objective To analyze the effect of pancreatoduodenectomy combined with Gimeracil and Oteracil Porassium on the prognosis and immune function in elderly patients with pancreatic cancer. Method 80 cases of elderly patients with pancreatic cancer treated in our hospital from January 2011 to January 2014 were selected. A all the patients were randomly divided into control group and study group, 40 cases in each group. Both groups patients underwent pancreatoduodenectomy, control group patients received gemcitabine postoperative adjuvant chemotherapy and study group patients received Gimeracil and Oteracil Porassium postoperative adjuvant chemotherapy. Compared the serum levels of tumor markers and immunoglobulin （Ig）, short-term effects, incidence of adverse reactions and the survival rates between the two groups. Result After treatment, the serum levels of CA19-9, CA50, CA125 and CA242 in the two groups were lower than before treatment （P 〈 0.05）, the levels of serum tumor markers in study group were significantly lower than control group （P 〈 0.05）. After treatment, the serum levels of IgG, IgA and IgM in the two groups were higher than before treatment （P 〈 0.05）. The levels of Ig in study group were significantly higher than control group （P 〈 0.05）. The total effective rate of study group was significantly higher than control group （χ^2 = 4.013, P 〈 0.05）. There were no significant differences between the two groups in the incidence of anorexia, fatigue, nausea, rash, diarrhea and incidence of total adverse reactions （P 〉 0.05）. 6 months, 1 year and 2 years after treatment, the survival rate of study group was better than control group （P 〈 0.05）. Conclusion The curative effect of pancreatoduodenectomy combined with Gimeracil and Oteracil Porassium in the treatment of elderly patients with pancreatic cancer is accurate, can significantly improve the patients＇ immune function and prognosis.
出处
《中国医学前沿杂志（电子版）》
2016年第6期172-175,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
替吉奥
吉西他滨
胰头十二指肠切除术
胰腺癌
预后
免疫功能
Gimeracil and Oteracil Porassium
Gemcitabine
Pancreatoduodenectomy
Pancreatic cancer
Prognosis
Immune function
